4,600 Shares in Quest Diagnostics Incorporated $DGX Bought by Canada Pension Plan Investment Board

Key Points

• Canada Pension Plan Investment Board acquired 4,600 Quest Diagnostics shares worth approximately $975,000, while institutional investors collectively own 88.06% of the company.
• Quest Diagnostics reported quarterly EPS of $3.12, beating estimates by $0.30, with revenue rising 10.2% year over year to $3.04 billion. The company maintained fiscal 2026 EPS guidance of $11.05–$11.25.
• The company declared a quarterly dividend of $0.86 per share, representing a 1.4% annualized yield, while analysts gave the stock a consensus “Moderate Buy” rating and a $235.31 target price.

Canada Pension Plan Investment Board purchased a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 4,600 shares of the medical research company's stock, valued at approximately $975,000.

Other large investors have also added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd increased its stake in shares of Quest Diagnostics by 178.7% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 171,987 shares of the medical research company's stock worth $29,847,000 after acquiring an additional 110,280 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Quest Diagnostics by 39.1% during the second quarter. Assenagon Asset Management S.A. now owns 15,405 shares of the medical research company's stock worth $3,265,000 after purchasing an additional 4,334 shares during the last quarter. BlackRock Inc. acquired a new position in Quest Diagnostics during the second quarter valued at $1,965,923,000. SGL Investment Advisors Inc. acquired a new position in Quest Diagnostics during the second quarter valued at $6,485,000. Finally, International Assets Investment Management LLC purchased a new stake in Quest Diagnostics in the fourth quarter valued at $92,000. Hedge funds and other institutional investors own 88.06% of the company's stock.

Quest Diagnostics Stock Performance

Shares of NYSE DGX opened at $240.96 on Tuesday. The company's fifty day moving average price is $224.91 and its 200 day moving average price is $207.46. Quest Diagnostics Incorporated has a 1 year low of $171.18 and a 1 year high of $247.19. The company has a market capitalization of $26.59 billion, a PE ratio of 25.58, a price-to-earnings-growth ratio of 2.24 and a beta of 0.56. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.46 and a current ratio of 1.59.

Quest Diagnostics (NYSE:DGX - Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, beating the consensus estimate of $2.82 by $0.30. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The company had revenue of $3.04 billion for the quarter, compared to analyst estimates of $2.97 billion. During the same quarter last year, the business earned $2.62 earnings per share. The firm's revenue was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, research analysts predict that Quest Diagnostics Incorporated will post 11.15 earnings per share for the current year.

Quest Diagnostics Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be given a dividend of $0.86 per share. The ex-dividend date is Tuesday, October 6th. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.4%. Quest Diagnostics's dividend payout ratio (DPR) is 36.52%.

Analysts Set New Price Targets

DGX has been the topic of several analyst reports. Robert W. Baird increased their price target on Quest Diagnostics from $236.00 to $255.00 and gave the stock a "neutral" rating in a research report on Friday, July 24th. Argus set a $260.00 price objective on Quest Diagnostics in a report on Wednesday, July 29th. Wall Street Zen upgraded Quest Diagnostics from a "hold" rating to a "buy" rating in a research note on Tuesday, July 28th. Mizuho raised their target price on Quest Diagnostics from $235.00 to $260.00 and gave the stock an "outperform" rating in a report on Friday, July 24th. Finally, Barclays raised their target price on Quest Diagnostics from $230.00 to $250.00 and gave the stock an "overweight" rating in a report on Thursday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $235.31.

Insider Activity at Quest Diagnostics

In related news, SVP Karthik Kuppusamy sold 8,147 shares of the company's stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $200.00, for a total value of $1,629,400.00. Following the completion of the transaction, the senior vice president owned 13,510 shares of the company's stock, valued at approximately $2,702,000. This represents a 37.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Michael E. Prevoznik sold 22,677 shares of the firm's stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $243.11, for a total value of $5,513,005.47. Following the completion of the sale, the senior vice president directly owned 37,557 shares in the company, valued at approximately $9,130,482.27. The trade was a 37.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 32,424 shares of company stock worth $7,518,693 in the last 90 days. Corporate insiders own 0.88% of the company's stock.

About Quest Diagnostics

Quest Diagnostics NYSE: DGX is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.